GemOx

GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin's lymphoma and Hodgkin's lymphoma.

When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R.

The [R]-GemOx regimen consists of:

  1. (R)ituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells;
  2. (Gem)citabine - an antimetabolite;
  3. (Ox)aliplatin - a platinum-based alkylating antineoplastic agent.[1][2]

Dosing regimen

[edit]
Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 1
(Gem)citabine 1000 mg/m2 IV infusion in 500 ml normal saline with the speed of 10 mg/m2/min Day 2
(Ox)aliplatin 100 mg/m2 IV infusion over 2hrs Day 2

References

[edit]